-
Product Insights
NewNorovirus Infections – Drugs In Development, 2024
Empower your strategies with our Norovirus Infections – Drugs In Development, 2024 report and make more profitable business decisions. Noroviruses are nonenveloped, positive-sense, single-stranded RNA viruses belonging to the Caliciviridae viral family. It is a highly contagious virus causing gastroenteritis, leading to stomach and intestinal inflammation. A common cause of outbreaks of diarrhea and vomiting in schools, cruise ships, hospitals, and community gatherings, it's nicknamed the "winter vomiting bug" due to prevalence in colder months. Symptoms encompass nausea, vomiting, diarrhea, and...
-
Product Insights
NewSeasonal Influenza – Drugs In Development, 2024
Empower your strategies with our Seasonal Influenza – Drugs In Development, 2024 report and make more profitable business decisions. Seasonal influenza, commonly referred to as "the flu", is a contagious respiratory illness caused by influenza viruses. It typically occurs in outbreaks during the fall and winter months, peaking between December and February in the Northern Hemisphere. The flu can cause mild to severe illness and, in some cases, can lead to hospitalization or even death, especially among vulnerable populations. Symptoms of...
-
Product Insights
NewZika Virus Infections – Drugs In Development, 2024
Empower your strategies with our Zika Virus Infections – Drugs In Development, 2024 report and make more profitable business decisions. Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Zika virus is a member of the Flaviviridae family. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include being in tropical and subtropical areas. Zika virus can also be transmitted through sexual intercourse. Treatment is aimed at relieving symptoms (joint pain...
-
Product Insights
Zika Virus Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Zika Virus Infections Pipeline Drugs Market Report Overview Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include being in tropical and subtropical areas. Zika virus can be transmitted through sexual intercourse. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications. The Zika Virus Infections pipeline drugs market research report provides comprehensive information on the Zika...
-
Product Insights
Rhinovirus Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Rhinovirus Infections pipeline market research report provides comprehensive information on the therapeutics under development for Rhinovirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rhinovirus Infections and features dormant and...
-
Product Insights
Genital Herpes Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Genital Herpes Pipeline Drugs Market Overview Genital Herpes is a common sexually transmitted infection that affects both men and women. Genital herpes is caused by the herpes simplex virus (HSV). Symptoms include decreased appetite, fever, general sick feeling (malaise), muscle aches in the lower back, buttocks, thighs, or knees and swollen and tender lymph nodes in the groin during an outbreak. Treatment includes antiviral medications. The Genital Herpes - drugs in development research report provides a comprehensive overview on the...
-
Sector Analysis
Outlook for Viral Vector Contract Manufacturing – Gene Therapies, Cell Therapies, and COVID-19 Vaccines
The bio/pharmaceutical industry is experiencing a shortage of viral vectors, a component needed to produce gene therapies and gene-modified cell therapies, as well as certain COVID-19 vaccines that require a viral vector, notably those from AstraZeneca and Johnson & Johnson (J&J). This report reveals that viral vector production is limited by insufficient manufacturing capacity, an inefficient manufacturing process, and the requirement for complex specialist facilities. There are 14 therapies/vaccines that use a viral vector (gene therapies, gene-modified cell therapies, and...
-
Sector Analysis
Coronavirus Disease 2019 (COVID-19) Vaccines – Contract Development and Manufacturing Landscape
This expert trend report is a comprehensive look at the contract manufacturing landscape surrounding COVID-19 Vaccine in 2020, including analysis of pipeline drugs, clinical trials, CMO activity, Contract Manufacturing Service Agreements, and funding for manufacturing of COVID-19 Vaccines. It is a critical source for strategic planning efforts and will improve understanding of crucial components of the supply chain that will provide insights for supplier selection and management.